Clinical trial
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
NCT00003171 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003171 |
|---|---|
| Title | Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | bryostatin 1 |
| Start date | May 1, 1998 |
| Primary completion | Jul 1, 1999 |
| Completion | Jun 1, 2003 |
| First posted | Jul 19, 2004 |
| Last update posted | Apr 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: